scholarly journals A Systematic Review of Conventional Therapy and Role of Stem Cell Transplantation for Primary Plasma Cell Leukemia

2018 ◽  
Vol 24 (3) ◽  
pp. S253-S254
Author(s):  
Amar Lal ◽  
Abdul Rauf ◽  
Zabih Warraich ◽  
Ahmad Iftikhar ◽  
Faiza Hassan Warraich ◽  
...  
Keyword(s):  
Systematic Review ◽  
Stem Cell ◽  
Stem Cell Transplantation ◽  
Cell Transplantation ◽  
Plasma Cell ◽  
Conventional Therapy ◽  
Plasma Cell Leukemia ◽  
Cell Leukemia ◽  
Primary Plasma Cell Leukemia

scholarly journals Primary plasma cell leukemia and autologous stem cell transplantation

Haematologica ◽  
2010 ◽  
Vol 95 (5) ◽  
pp. 804-809 ◽  
Author(s):  
M. B. Drake ◽  
S. Iacobelli ◽  
A. van Biezen ◽  
C. Morris ◽  
J. F. Apperley ◽  
...  
Keyword(s):  
Stem Cell ◽  
Stem Cell Transplantation ◽  
Cell Transplantation ◽  
Autologous Stem Cell Transplantation ◽  
Plasma Cell ◽  
Plasma Cell Leukemia ◽  
Cell Leukemia ◽  
Primary Plasma Cell Leukemia

Bortezomib, Doxorubicin, Cyclophosphamide, Dexamethasone Induction Followed by Stem Cell Transplantation for Primary Plasma Cell Leukemia: A Prospective Phase II Study of the Intergroupe Francophone du Myélome

2016 ◽  
Vol 34 (18) ◽  
pp. 2125-2132 ◽  
Author(s):  
Bruno Royer ◽  
Stéphane Minvielle ◽  
Momar Diouf ◽  
Murielle Roussel ◽  
Lionel Karlin ◽  
...  
Keyword(s):  
Stem Cell ◽  
Stem Cell Transplantation ◽  
Cell Transplantation ◽  
Plasma Cell ◽  
Phase Ii ◽  
Cell Leukemia ◽  
Reduced Intensity Conditioning ◽  
Prospective Phase ◽  
Primary Plasma Cell Leukemia ◽  
Reduced Intensity

Purpose Primary plasma cell leukemia (pPCL) is a rare and aggressive malignancy with a poor prognosis. With conventional chemotherapy, patients typically die within 1 year. In all but one of the retrospective studies reported to date, bortezomib and lenalidomide seem to improve survival. We conducted a prospective phase II trial in patients with pPCL to assess the efficacy of an alternate regimen that combines standard chemotherapy, a proteasome inhibitor, and high-dose melphalan and autologous stem cell transplantation (HDM/ASCT) followed by either allogeneic transplantation or bortezomib/lenalidomide maintenance. Patients and Methods Patients 70 years old and younger with newly diagnosed pPCL received four alternating cycles of bortezomib, dexamethasone plus doxorubicin or cyclophosphamide. Peripheral blood stem cells were collected from responding patients with < 1% of circulating plasma cells before HDM/ASCT. As consolidation, young patients received a reduced-intensity conditioning allograft, whereas the remaining patients underwent a second HDM/ASCT followed by 1 year of bortezomib, lenalidomide, dexamethasone. The primary end point was progression-free survival (PFS). Results Forty patients (median age, 57 years; range, 27 to 71 years) were enrolled. The median follow-up was 28.7 months. In the intention-to-treat analysis, the median PFS and overall survival were 15.1 (95% CI, 8.4; -) and 36.3 (95% CI, 25.6; -) months, respectively. The overall response rate to induction was 69%. One patient underwent a syngeneic allograft and 25 HDM/ASCT (16 of whom subsequently received a reduced-intensity conditioning allograft and seven a second ASCT followed by maintenance). Conclusion In this prospective trial in patients with pPCL, we show that bortezomib, dexamethasone plus doxorubicin or cyclophosphamide induction followed by transplantation induces high response rates and appears to significantly improve PFS.

Sign in / Sign up

Export Citation Format

Share Document